A Qualitative Analysis of the Impact of Carboplatin AUC 10 on Physical, Work Functioning and Bone Marrow Toxicity Among Seminoma Patients - A Single-centre Experience.
Adult
Aged
Bone Marrow
/ drug effects
Carboplatin
/ administration & dosage
Cisplatin
/ administration & dosage
Disease-Free Survival
Drug-Related Side Effects and Adverse Reactions
/ classification
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
/ blood
Neutropenia
/ chemically induced
Quality of Life
Seminoma
/ blood
Thrombocytopenia
/ chemically induced
Treatment Outcome
Seminoma
bone marrow
carboplatin
toxicity
work functioning
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
15
10
2018
revised:
26
10
2018
accepted:
01
11
2018
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
5
4
2019
Statut:
ppublish
Résumé
Single-agent carboplatin at area under the curve 10 (AUC10) is an effective treatment for metastatic seminoma. As far as we are aware of, there have been no studies reporting its effects on short-term quality of life. The objective was to study the efficacy, safety and tolerability, using health-related quality of life, of carboplatin AUC10 chemotherapy in patients with metastatic seminoma. Forty-four patients with metastatic seminoma treated at Mount Vernon Cancer Centre with carboplatin AUC10 were included in this study. Response to treatment was determined by radiological imaging (Response Evaluation Criteria in Solid Tumors v 1.1) and serum tumour markers. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. Quality of life treatment-related toxicities were assessed during treatment at pre-chemotherapy assessments. After treatment, toxicity was assessed using a defined telephone questionnaire consisting of four questions relating to hair loss, hearing impairment, days absent from work, and neuropathy. At a median follow-up of 27.5 (range=4-84) months, no patient had experienced relapse. Grade 3/4 neutropenia was seen in 15 (35%) patients, nine (21%) required prophylactic granulocyte colony-stimulating factor, 13 (30%) patients had grade 3/4 thrombocytopenia. Commonest non-haematological toxicities were fatigue in 28 (65%) and nausea 14 (33%) patients. They were grade 1 in 82% and 92% of cases, respectively. Six out of 44 (14%) had residual tinnitus. One patient had residual grade 1 peripheral neuropathy. Ten patients continued to work throughout treatment and two patients were retired. Of the remaining patients, 16 (37%), took fewer than 5 days off work. Carboplatin AUC10 is a safe and effective treatment for stage II/III seminoma with better health-related quality of life than experienced with combination cisplatin-based chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Single-agent carboplatin at area under the curve 10 (AUC10) is an effective treatment for metastatic seminoma. As far as we are aware of, there have been no studies reporting its effects on short-term quality of life. The objective was to study the efficacy, safety and tolerability, using health-related quality of life, of carboplatin AUC10 chemotherapy in patients with metastatic seminoma.
PATIENTS AND METHODS
METHODS
Forty-four patients with metastatic seminoma treated at Mount Vernon Cancer Centre with carboplatin AUC10 were included in this study. Response to treatment was determined by radiological imaging (Response Evaluation Criteria in Solid Tumors v 1.1) and serum tumour markers. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. Quality of life treatment-related toxicities were assessed during treatment at pre-chemotherapy assessments. After treatment, toxicity was assessed using a defined telephone questionnaire consisting of four questions relating to hair loss, hearing impairment, days absent from work, and neuropathy.
RESULTS
RESULTS
At a median follow-up of 27.5 (range=4-84) months, no patient had experienced relapse. Grade 3/4 neutropenia was seen in 15 (35%) patients, nine (21%) required prophylactic granulocyte colony-stimulating factor, 13 (30%) patients had grade 3/4 thrombocytopenia. Commonest non-haematological toxicities were fatigue in 28 (65%) and nausea 14 (33%) patients. They were grade 1 in 82% and 92% of cases, respectively. Six out of 44 (14%) had residual tinnitus. One patient had residual grade 1 peripheral neuropathy. Ten patients continued to work throughout treatment and two patients were retired. Of the remaining patients, 16 (37%), took fewer than 5 days off work.
CONCLUSION
CONCLUSIONS
Carboplatin AUC10 is a safe and effective treatment for stage II/III seminoma with better health-related quality of life than experienced with combination cisplatin-based chemotherapy.
Identifiants
pubmed: 30587629
pii: 33/1/233
doi: 10.21873/invivo.11465
pmc: PMC6364087
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-237Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
World J Urol. 1999 Aug;17(4):230-8
pubmed: 10460406
Int J Cancer. 1999 Dec 10;83(6):823-7
pubmed: 10597202
Br J Cancer. 2000 Dec;83(12):1623-9
pubmed: 11104556
Bone Marrow Transplant. 2002 Nov;30(9):593-7
pubmed: 12407434
J Clin Oncol. 2002 Nov 15;20(22):4448-52
pubmed: 12431967
Cancer. 2003 Aug 15;98(4):745-52
pubmed: 12910518
J Clin Oncol. 2004 Feb 15;22(4):640-7
pubmed: 14726503
Eur J Cancer. 1992;28A(8-9):1307-10
pubmed: 1515239
Nucl Med Commun. 2004 Aug;25(8):759-69
pubmed: 15266169
Br J Cancer. 2004 Aug 16;91(4):683-7
pubmed: 15266338
Ann Oncol. 2006 Feb;17(2):276-80
pubmed: 16254023
Postgrad Med J. 2007 Oct;83(984):624-32
pubmed: 17916870
J Clin Oncol. 2008 Nov 20;26(33):5416-21
pubmed: 18936476
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Ann Oncol. 2010 Aug;21(8):1730-1
pubmed: 20530199
J Adolesc Health. 2010 Aug;47(2):115-25
pubmed: 20638003
Psychooncology. 2011 Jul;20(7):738-45
pubmed: 20878864
Urol Oncol. 2013 Jul;31(5):697-705
pubmed: 21665493
Acta Oncol. 2013 Jun;52(5):987-93
pubmed: 22943385
Br J Cancer. 2014 Jan 7;110(1):256-63
pubmed: 24263066
J Natl Cancer Inst. 2014 Sep 29;106(9):null
pubmed: 25265940
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Front Pharmacol. 2016 May 13;7:122
pubmed: 27242529
Eur J Cancer. 2017 Oct;84:354-359
pubmed: 28866371
Laryngoscope. 1988 Aug;98(8 Pt 1):858-64
pubmed: 3398663
Cancer Treat Rep. 1982 Jan;66(1):19-23
pubmed: 7198012
J Clin Oncol. 1994 Jan;12(1):120-6
pubmed: 7505805
J Urol. 1996 Feb;155(2):574-8
pubmed: 8558663
J Clin Oncol. 1997 May;15(5):1837-43
pubmed: 9164193
J Clin Oncol. 1998 Feb;16(2):702-6
pubmed: 9469360
Br J Cancer. 1998 Apr;77(8):1355-62
pubmed: 9579846